428 related articles for article (PubMed ID: 15980902)
1. Benzbromarone therapy in management of refractory gout.
Kumar S; Ng J; Gow P
N Z Med J; 2005 Jun; 118(1217):U1528. PubMed ID: 15980902
[TBL] [Abstract][Full Text] [Related]
2. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
4. [Therapy with alllopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's transl)].
Mertz DP
Med Klin; 1977 Apr; 72(15):664-8. PubMed ID: 857138
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Hanvivadhanakul P; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
[TBL] [Abstract][Full Text] [Related]
6. [The effect of benzbromaron in gout patients with limited kidney function].
Kuzmits R; Bresnik W; Müller MM
Fortschr Med; 1979 Nov; 97(44):2057-61. PubMed ID: 511087
[TBL] [Abstract][Full Text] [Related]
7. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Matzkies F
Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
[TBL] [Abstract][Full Text] [Related]
8. Gout--what are the treatment options?
Schlesinger N; Dalbeth N; Perez-Ruiz F
Expert Opin Pharmacother; 2009 Jun; 10(8):1319-28. PubMed ID: 19463070
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
[TBL] [Abstract][Full Text] [Related]
12. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
Mertz DP
Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
[No Abstract] [Full Text] [Related]
13. [Effect of benziodarone and benzbromarone on the uric acid level in the blood and urine and on the incidence of gout attacks].
Brzozowska-Jurkowska AM
Reumatologia; 1980; 18(3):287-92. PubMed ID: 6999575
[No Abstract] [Full Text] [Related]
14. [Clinical studies on hyperuricemia and gout after transplantation].
Imanishi M; Ikegami M; Ishii T; Nishioka T; Uemura T; Kunikata S; Kanda H; Matsuura T; Akiyama T; Kurita T
Hinyokika Kiyo; 1990 Aug; 36(8):893-6. PubMed ID: 2239590
[TBL] [Abstract][Full Text] [Related]
15. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
Matzkies F; Neuwirth R; Berg G
Fortschr Med; 1976 Sep; 94(26):1427-9. PubMed ID: 976920
[TBL] [Abstract][Full Text] [Related]
16. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
17. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
18. Influence of urate-lowering therapies on renal handling of uric acid.
Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
[TBL] [Abstract][Full Text] [Related]
19. Ten years' experience with benzbromarone in the management of gout and hyperuricaemia.
Masbernard A; Giudicelli CP
S Afr Med J; 1981 May; 59(20):701-6. PubMed ID: 7221794
[TBL] [Abstract][Full Text] [Related]
20. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
